Today: 11 June 2026
Browse Category

ASX:RWC 8 January 2026

Stock Market Today

  • Theriva Biologics Shares Surge 75% on VCN-01 Phase 1 Cancer Trial Data
    June 11, 2026, 11:01 AM EDT. Theriva Biologics' stock (TOVX) jumped 74.6% after publication of Phase 1 trial results for its cancer drug VCN-01 in Clinical Cancer Research. The study targeted head-and-neck squamous cell carcinoma, showing median overall survival between 10.3 and 17.3 months across dosing groups. VCN-01 is an oncolytic adenovirus designed to break down tumor cells and enhance immune checkpoint inhibitor efficacy, used alongside AstraZeneca's durvalumab. Biomarker data confirmed immune activation signals, suggesting VCN-01 may resensitize tumors to treatment. Despite the rally, risks remain including financing, dilution, and clinical trial execution. Theriva's market cap stayed under $20 million amid high trading volumes, reflecting investor interest in immuno-oncology advances.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop